Stemtech Corporation (STEK) Fair Value 2026

STEK · Wholesale-Drugs, Proprietaries & Druggists' Sundries ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (42/100)

Quick Summary — As of 2026-08-27, Stemtech Corporation (STEK) trades at $0.00. QOC: 4.5/10. Value Trap Risk: 42/100 (WARN). 1/13 models active.

Key Facts

Ticker
STEK
Price
$0.00
Quality Score
4.5/10
Value Trap Risk
42/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +458.5% upside with 30% confidence
Risk: Value Trap score of 42 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give STEK?

1 Intrinsic Value Models vs. Current Price ($0.00)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $0.00 +458.5%

All Models Active

All 1 models are displayed above.

What Is Stemtech Corporation (STEK) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Stemtech Corporation is potentially undervalued at its current price of $0.00. Based on our 13-model framework, Stemtech Corporation's intrinsic value is estimated at a median fair value of $0.00 — representing +458.5% implied upside — with 1 out of 1 active models confirming this thesis.

What Do the Models Say About STEK?

1 of 13 models are currently active for STEK. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does STEK Rank in Wholesale-Drugs, Proprietaries & Druggists' Sundries?

Among 1 Wholesale-Drugs, Proprietaries & Druggists' Sundries stocks, STEK ranks #1 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.

As a biopharma enterprise, Stemtech Corporation operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating STEK should weigh these sector-specific dynamics alongside our model-derived fair values.

Is STEK a Value Trap?

CirclFi's Value Trap algorithm assigns STEK a score of 42/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Stemtech Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Stemtech Corporation's fundamental quality profile registers 4.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every STEK valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across STEK's 1 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Stemtech Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Other Stocks Have a Similar Quality Score to STEK?

7 companies across all industries closest to STEK’s Quality of Company score of 4.5/10.

HINDVyome Holdings, Inc.QOC 4.5SPWRSunPower Inc.QOC 4.5GPOXGPO Plus, Inc.QOC 4.5UNCYUnicycive Therapeutics, Inc.QOC 4.5BSPKBespoke Extracts, Inc.QOC 4.5ELDNEledon Pharmaceuticals, Inc.QOC 4.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HIND · SPWR · GPOX · UNCY · BSPK · ELDN · NVDA

What Else Do Investors Ask About Stemtech Corporation’s Valuation?

What is Stemtech Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Stemtech Corporation (STEK). The Quality of Company score is 4.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is STEK overvalued or undervalued right now?

At $0.00, 1 of 1 active models suggest STEK may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Stemtech Corporation's business model in Wholesale-Drugs, Proprietaries & Druggists' Sundries.

What does a Quality of Company score of 4.5 mean for STEK?

Stemtech Corporation's QOC of 4.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on STEK?

CirclFi analyzes STEK with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is STEK a value trap in 2026?

Stemtech Corporation's Value Trap score is 42/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Stemtech Corporation (STEK) a Quality of Company score of 4.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/STEK/ · Methodology
Primary sources for this STEK valuation
  • Financial statements: Stemtech Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001511820) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for STEK as of ; valuations recomputed .